Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Aspirin for COVID-19: real-time meta analysis of 23 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19aspirin.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] death 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Liu (PSM) 81% 0.19 [0.05-0.78] death 1/28 9/204 Liu (PSM) -2% 1.02 [0.64-1.61] viral time 24 (n) 24 (n) Mura (PSM) 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Mura (PSM) 37% 0.63 [0.47-0.83] death 305 (n) 305 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Chow 44% 0.56 [0.37-0.85] ventilation 35/98 152/314 Chow 43% 0.57 [0.38-0.85] ICU 38/98 160/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Al Harthi (PSM) 27% 0.73 [0.56-0.97] death 98/176 107/173 Al Harthi (PSM) 14% 0.86 [0.65-1.14] death 95/176 97/175 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Kim (PSM) -102% 2.02 [0.83-4.90] ventilation 13/124 7/135 Kim (PSM) -91% 1.91 [0.57-6.35] ICU 7/124 4/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 Zhao 28% 0.72 [0.54-0.96] death 473 (n) 1,597 (n) RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) RECOVERY (RCT) 17% 0.83 [0.66-1.04] death 7,351 (n) 7,541 (n) RECOVERY (RCT) 5% 0.95 [0.87-1.05] ventilation 7,351 (n) 7,541 (n) RECOVERY (RCT) 6% 0.94 [0.91-0.98] no disch. 7,351 (n) 7,541 (n) RECOVERY (RCT) 16% 0.84 [0.71-0.99] no disch. 7,351 (n) 7,541 (n) Mustafa 44% 0.56 [0.21-1.51] death 4/66 41/378 Huh 71% 0.29 [0.14-0.58] cases population-based cohort Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Osborne (PSM) 60% 0.40 [0.33-0.48] death 170/6,814 427/6,814 Merzon 28% 0.72 [0.53-0.99] cases 73/1,621 589/8,856 Merzon 62% 0.38 [0.02-4.94] death 1/21 6/91 Merzon 10% 0.90 [0.82-1.00] viral time 73 (n) 589 (n) Merzon 15% 0.85 [0.76-0.95] viral time 73 (n) 589 (n) Mulhem -14% 1.14 [0.93-1.40] death 300/1,354 216/1,865 Chow (PSM) 19% 0.81 [0.76-0.87] death 1,280/6,781 2,271/10,566 Chow (PSM) 3% 0.97 [0.93-1.02] ventilation 2,122/6,781 3,403/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] death 6/15 1/20 Kim (PSM) -433% 5.33 [0.66-43.0] ventilation 4/15 1/20 Kim (PSM) -433% 5.33 [0.66-43.0] ICU 4/15 1/20 Kim (PSM) 33% 0.67 [0.30-1.36] cases 15/136 20/136 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Kim (PSM) -102% 2.02 [0.83-4.90] ventilation 13/124 7/135 Kim (PSM) -91% 1.91 [0.57-6.35] ICU 7/124 4/135 Basheer -13% 1.13 [1.05-1.21] death 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] death 93/253 251/731 Sisinni 30% 0.70 [0.53-0.92] int./death 253 (n) 731 (n) PĂ©rez-Segura -49% 1.49 [1.20-1.80] death 66/155 183/608 aspirin COVID-19 outcomes c19aspirin.com Jan 18, 2022 Favors aspirin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit